Study shows PDE5 inhibitor more effective when used on demand in erectile dysfunctionAugust 27, 2008European Urology (www.europeanurology.com), the official journal of the European Association of Urology will be featuring the article 'Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy' by F. Montorsi et al.in the October issue, showing for the first time that vardenafil, a PDE5 inhibitor, is more efficacious when used on-demand in men with erectile dysfunction, supporting a shift towards on-demand dosing with PDE5 inhibitors in this patient group. 87 centres across Europe, the US, Canada and South Africa participated between December 2004 and September 2007. Nerve-sparing radical prostatectomy (NSRP) is the gold-standard therapy for prostate cancer in men with a life expectancy of 10 years or more. The risk of erectile dysfunction (ED) following NSRP is significant. This is caused by neuropraxia - the usually temporary failure of nerve conduction in the absence of structural changes due to compression, ischemia or blunt injury - which inevitably occurs during the procedure. Ultimately this may lead to the development of fibrosis within the corpus cavernosa and cause ED. To prevent the onset of postoperative ED, the use of phosphodiesterase type 5 (PDE5) inhibitors was introduced. These agents prevent the breakdown of cyclic guanosine monophosphate in cavernosal tissue, which plays a role in the prevention of cell death and fibrosis, and may thus exert a protective effect on cavernosal smooth muscle.
Participants were recruited to this first robustly designed, evidence-based, multi-centre study approximately one month before they were scheduled to undergo NSRP. A total of 423 patients completed the study. The inclusion of the on-demand dosing regimen enabled comparison of the currently recommended guidelines for the use of PDE5 inhibitors with a proposed nightly dosing regimen, which was suggested to have potential positive effects on erectile function. The results clearly show that nightly dosing with vardenafil does not have any effect beyond that of on-demand use. The study shows that on-demand use of vardenafil during the treatment period was associated with significantly greater erectile function and sexual intercourse completion rates compared to placebo. The success rates for the vardenafil on-demand group were also higher than for the nightly group. These data indicate that the use of on-demand vardenafil is of greater benefit than nightly treatment in patients following NSRP surgery and, in general, support the on-demand use of PDE5 inhibitors following NSRP surgery over a daily dosing regimen. This prompts reconsideration of the current practice of prescribing nightly PDE5 inhibitor therapy, as on-demand use of vardenafil is equally effective in men with ED following NSRP, a notoriously difficult-to-treat patient population. Elsevier | |||||||||||||||||||||
|
Related Erectile Dysfunction Current Events and Erectile Dysfunction News Articles OHSU Cancer Institute researchers study breathing during radiation Oregon Health & Science University researchers have determined exactly how much breathing affects prostate movement during radiation treatment. Erectile dysfunction related to sleep apnea may persist, but is treatable For sufferers of sleep apnea, erectile dysfunction (ED) is often part of the package. New research indicates that ED in cases of obstructive sleep apnea syndrome (OSAS) may be linked to the chronic intermittent hypoxia-oxygen deprivation- (CIH) that patients with OSAS experience during episodes of obstructed breathing. Young Type-2 Diabetic Men Suffer Low Testosterone Levels, Study Shows Young men with type 2 diabetes have significantly low levels of testosterone, endocrinologists at the University at Buffalo have found -- a condition that could have a critical effect on their quality of life and on their ability to father children. Tadalafil shows promise for relief of lower urinary tract symptoms associated with BPH Men with signs of benign prostatic hyperplasia (BPH) can be helped with a daily dose of erectile dysfunction drug tadalafil (Cialis®) to relieve associated lower urinary tract symptoms (LUTS), according to a new study published in the October 2008 issue of The Journal of Urology. Researchers examine safety of Internet prescriber service providing erectile dysfunction medications Online Internet shopping today offers many benefits. You can research a product in the privacy of your own home and purchase most anything by clicking a mouse. Causes for sexual dysfunction change as people age Sexual dysfunction is not an inevitable part of aging, but it is strongly related a number of factors, such as mental and physical health, demographics and lifetime experiences, many of which are interrelated, according to a new study by researchers at the University of Chicago. Male circumcision efforts lag in Africa despite evidence of dramatic impact in preventing HIV With millions of lives at stake over the next two decades, researchers and advocates at the AIDS 2008 Conference today called on the global health community to ramp up male circumcision to significantly reduce risk of HIV infection in Africa, and to move quickly to integrate the life-saving procedure into other comprehensive efforts to prevent transmission of the disease in the vulnerable nations of eastern and southern Africa. Erectile dysfunction drugs allowed more chemotherapy to reach brain tumors in laboratory study In a study using laboratory animals, researchers found that medications commonly prescribed for erectile dysfunction opened a mechanism called the blood-brain tumor barrier and increased delivery of cancer-fighting drugs to malignant brain tumors. NIDDK Publishes a Strategic Plan for Research into Benign Prostate Disease For the first time, a strategic plan for research into benign prostate disease, based on the latest scientific knowledge, has been published by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health (NIH). Prostate cancer patients undergoing hormone therapy may experience cognitive effects A recent review of the literature has found that hormone deprivation therapy, a commonly used treatment for prostate cancer, may have subtle adverse effects on cognition in patients-- such as in the ability to recall and concentrate. More Erectile Dysfunction Current Events and Erectile Dysfunction News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||